References
- SteinerJFProchazkaAVThe assessment of refill compliance using pharmacy records: methods, validity, and applicationsJ Clin Epidemiol19975011051169048695
- HaynesRBA critical review of the “determinants” of patient compliance with therapeutic regimensSackettDLHaynesRBCompliance with therapeutic regimensBaltimore, MDJohns Hopkins University Press19762639
- ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
- CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
- KennaLALabbeLBarrettJSPfisterMModeling and simulation of adherence: approaches and applications in therapeuticsAAPS J200572E390E40716353919
- MacleanRPfisterMZhouZQuantifying the impact of nonadherence patterns on exposure to oral immunosuppressantsTher Clin Risk Manag20112011714915621691585
- US Food Drug AdministrationHUMIRA (adalimumab) [prescribing information;]ChicagoAbbott Laboratories2002
- US Food Drug AdministrationFDA approves Humira to treat ulcerative colitis [press release]Maryland,United StatesUS Food and Drug Administration2012
- TernantDDucourauEFuzibetPPharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritisBr J Clin Pharmacol201579228629725223394
- WestCNarahariSO’NeillJAdherence to adalimumab in patients with moderate to severe psoriasisDermatol Online J20131951818224011280
- ChiuYLRubinDTVermeireSSerum adalimumab concentration and clinical remission in patients with Crohn’s diseaseInflamm Bowel Dis20131961112112223584130
- BarteldsGMWijbrandtsCANurmohamedMTClinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnn Rheum Dis200766792192617301106
- RoblinXMarotteHRinaudoMAssociation between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseasesClin Gastroenterol Hepatol2014121808423891927
- den BroederAvan de PutteLRauRA single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritisJ Rheumatol200229112288229812415583
- WeismanMHMorelandLWFurstDEEfficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyClin Ther20032561700172112860493
- ClarkMColombelJFFeaganBCAmerican gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006Gastroenterology2007133131233917631151
- ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology20071321526517241859
- BarteldsGMKrieckaertCLNurmohamedMTDevelopment of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-upJAMA2011305141460146821486979